S&P 500   3,330.16 (+0.28%)
DOW   29,247.51 (+0.18%)
QQQ   224.65 (+0.61%)
AAPL   319.63 (+0.97%)
FB   222.18 (+0.33%)
MSFT   166.23 (-0.17%)
GOOGL   1,493.98 (+0.79%)
AMZN   1,893.37 (+0.07%)
CGC   24.45 (+1.24%)
NVDA   250.88 (+1.19%)
BABA   223.82 (+0.70%)
MU   59.31 (+0.58%)
GE   11.43 (-1.97%)
TSLA   579.81 (+5.96%)
AMD   51.47 (+0.82%)
T   39.05 (+1.38%)
ACB   2.06 (+2.49%)
F   9.20 (-0.22%)
NFLX   327.08 (-3.26%)
BAC   34.37 (+0.32%)
GILD   63.38 (+1.20%)
S&P 500   3,330.16 (+0.28%)
DOW   29,247.51 (+0.18%)
QQQ   224.65 (+0.61%)
AAPL   319.63 (+0.97%)
FB   222.18 (+0.33%)
MSFT   166.23 (-0.17%)
GOOGL   1,493.98 (+0.79%)
AMZN   1,893.37 (+0.07%)
CGC   24.45 (+1.24%)
NVDA   250.88 (+1.19%)
BABA   223.82 (+0.70%)
MU   59.31 (+0.58%)
GE   11.43 (-1.97%)
TSLA   579.81 (+5.96%)
AMD   51.47 (+0.82%)
T   39.05 (+1.38%)
ACB   2.06 (+2.49%)
F   9.20 (-0.22%)
NFLX   327.08 (-3.26%)
BAC   34.37 (+0.32%)
GILD   63.38 (+1.20%)
S&P 500   3,330.16 (+0.28%)
DOW   29,247.51 (+0.18%)
QQQ   224.65 (+0.61%)
AAPL   319.63 (+0.97%)
FB   222.18 (+0.33%)
MSFT   166.23 (-0.17%)
GOOGL   1,493.98 (+0.79%)
AMZN   1,893.37 (+0.07%)
CGC   24.45 (+1.24%)
NVDA   250.88 (+1.19%)
BABA   223.82 (+0.70%)
MU   59.31 (+0.58%)
GE   11.43 (-1.97%)
TSLA   579.81 (+5.96%)
AMD   51.47 (+0.82%)
T   39.05 (+1.38%)
ACB   2.06 (+2.49%)
F   9.20 (-0.22%)
NFLX   327.08 (-3.26%)
BAC   34.37 (+0.32%)
GILD   63.38 (+1.20%)
S&P 500   3,330.16 (+0.28%)
DOW   29,247.51 (+0.18%)
QQQ   224.65 (+0.61%)
AAPL   319.63 (+0.97%)
FB   222.18 (+0.33%)
MSFT   166.23 (-0.17%)
GOOGL   1,493.98 (+0.79%)
AMZN   1,893.37 (+0.07%)
CGC   24.45 (+1.24%)
NVDA   250.88 (+1.19%)
BABA   223.82 (+0.70%)
MU   59.31 (+0.58%)
GE   11.43 (-1.97%)
TSLA   579.81 (+5.96%)
AMD   51.47 (+0.82%)
T   39.05 (+1.38%)
ACB   2.06 (+2.49%)
F   9.20 (-0.22%)
NFLX   327.08 (-3.26%)
BAC   34.37 (+0.32%)
GILD   63.38 (+1.20%)
Log in
(Ad)
If you're happy with stocks yielding you 4% or 5% a year, you don't need this. But if you want to see how we built a portfolio that now pays us a 67% cash on cash return - with no leverage, options, or gimmicks.

NASDAQ:CBAY - CymaBay Therapeutics Stock Price, Forecast & News

$1.93
-0.02 (-1.03 %)
(As of 01/22/2020 02:17 PM ET)
Today's Range
$1.88
Now: $1.93
$1.99
50-Day Range
$1.65
MA: $1.89
$2.06
52-Week Range
$1.29
Now: $1.93
$14.00
Volume428,253 shs
Average Volume857,384 shs
Market Capitalization$132.59 million
P/E RatioN/A
Dividend YieldN/A
Beta1.13
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBAY
CUSIPN/A
Phone510-293-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10 million
Book Value$2.87 per share

Profitability

Net Income$-72,550,000.00

Miscellaneous

Employees43
Market Cap$132.59 million
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive CBAY News and Ratings via Email

Sign-up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter.


CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics Inc (NASDAQ:CBAY) issued its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.37) by $0.01. View CymaBay Therapeutics' Earnings History.

When is CymaBay Therapeutics' next earnings date?

CymaBay Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for CymaBay Therapeutics.

What price target have analysts set for CBAY?

13 brokers have issued twelve-month target prices for CymaBay Therapeutics' stock. Their forecasts range from $2.00 to $18.00. On average, they expect CymaBay Therapeutics' share price to reach $6.95 in the next twelve months. This suggests a possible upside of 260.3% from the stock's current price. View Analyst Price Targets for CymaBay Therapeutics.

What is the consensus analysts' recommendation for CymaBay Therapeutics?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 10 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for CymaBay Therapeutics.

What are Wall Street analysts saying about CymaBay Therapeutics stock?

Here are some recent quotes from research analysts about CymaBay Therapeutics stock:
  • 1. According to Zacks Investment Research, "CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. " (1/7/2020)
  • 2. HC Wainwright analysts commented, "916-3963, Rating POS Risk-adj value Full value Shares outstanding 68,696 S/O as of April 30, 2019. Current share price $6.05 Discount rate 20.0% Seladelpar (PBC) – U.S." (6/12/2019)
  • 3. Cantor Fitzgerald analysts commented, ". Reiterate our Overweight rating; increasing 12-mo. PT to $20. CymaBay is a liver disease company with lead asset, seladelpar, in Ph3 for primary biliary cholangitis (PBC). Our checks suggest seladelpar’s strong profile in PBC has the potential to grow the market significantly from where it is today. We think the opportunity in PBC alone (~$350M in 2026 unadjusted sales vs. cap of $500M) should justify upside. We see further potential for seladelpar with a 2Q19 Ph2b NASH proof of concept readout, which could be a much larger opportunity (~ $4B+) for Seladelpar if successful. In our 75-page slide deck, we took a close look at PPAR-delta biology & role in NASH. Our Take: PPAR-delta has the potential to be a major target in the NASH space." (2/1/2019)

Has CymaBay Therapeutics been receiving favorable news coverage?

Media coverage about CBAY stock has been trending negative on Wednesday, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. CymaBay Therapeutics earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for CymaBay Therapeutics.

Are investors shorting CymaBay Therapeutics?

CymaBay Therapeutics saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 7,160,000 shares, an increase of 5.3% from the November 28th total of 6,800,000 shares. Based on an average daily trading volume, of 2,070,000 shares, the short-interest ratio is currently 3.5 days. Approximately 11.7% of the shares of the company are short sold. View CymaBay Therapeutics' Current Options Chain.

Who are some of CymaBay Therapeutics' key competitors?

What other stocks do shareholders of CymaBay Therapeutics own?

Who are CymaBay Therapeutics' key executives?

CymaBay Therapeutics' management team includes the folowing people:
  • Mr. Sujal A. Shah, Pres, CEO & Director (Age 46)
  • Mr. Daniel Menold, VP of Fin. (Age 49)
  • Dr. Charles A. McWherter, Sr. VP & Chief Scientific Officer (Age 64)
  • Mr. Paul T. Quinlan, Gen. Counsel & Corp. Sec. (Age 56)
  • Dr. Pol F. Boudes, Chief Medical Officer (Age 62)

Who are CymaBay Therapeutics' major shareholders?

CymaBay Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Diversified Trust Co (0.03%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Daniel Menold, Kurt Von Emster and Sujal Shah. View Institutional Ownership Trends for CymaBay Therapeutics.

Which institutional investors are buying CymaBay Therapeutics stock?

CBAY stock was purchased by a variety of institutional investors in the last quarter, including Diversified Trust Co. View Insider Buying and Selling for CymaBay Therapeutics.

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $1.93.

How big of a company is CymaBay Therapeutics?

CymaBay Therapeutics has a market capitalization of $132.59 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-72,550,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. CymaBay Therapeutics employs 43 workers across the globe.View Additional Information About CymaBay Therapeutics.

What is CymaBay Therapeutics' official website?

The official website for CymaBay Therapeutics is http://www.cymabay.com/.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected]


MarketBeat Community Rating for CymaBay Therapeutics (NASDAQ CBAY)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  402 (Vote Outperform)
Underperform Votes:  282 (Vote Underperform)
Total Votes:  684
MarketBeat's community ratings are surveys of what our community members think about CymaBay Therapeutics and other stocks. Vote "Outperform" if you believe CBAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel